Experimental Therapy for Patients Who Have First Or Second Recurrent Glioblastoma
Eligible IDH1 Wild Type
We're evaluating an experimental placenta-derived cell therapy (CYNK-001) in patients with recurrent glioblastoma.
The purpose of this study is to test the safety and effectiveness of the investigational treatment, CYNK-001, in adults with Recurrent Glioblastoma. The study plans to identify the most appropriate dose of CYNK-001 and determine if the treatment may improve or worsen this condition.
The study can take up to approximately 26 months. Your doctor will advise if you should remain in the hospital and for how long during any period of the study. This may affect the number of visits you make to the treatment center.
Treatment Eligibility Screening Period: It will assess your eligibility to participate in the study (approximately 2-4 weeks)
- Treatment Period: Treatment will be given in two parts (approximately 1.5 months total):
- Lymphodepletion (3 days)
- CYNK-001 Treatment (36 days)
- Tumor resection surgery (1 Day)
- Follow-up Period: Tests will be performed to evaluate safety and disease status (approximately 24 months)
AGE: ≥18 years old
KEYWORDS: recurrent glioblastoma, placenta stem cells, resectable glioma, glioblastoma multiforme, brain tumor research, brain tumor surgery
TYPE: Phase 1/2a, Cellular Immunotherapy
TARGET: 66 Participants
WHO MAY PARTICIPATE?
(The study doctor will discuss and review with you the full list of study qualifications required to participate in this clinical trial)
Patients with recurrent Glioblastoma (first or second)
Patients greater or equal to 18 years of age
Patients who are willing and able to adhere to study procedures and attend study visits
Have any questions or want to learn more?
Please contact the site coordinator with your questions via email.